Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
about
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandVaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipientsPoxvirus vectors as HIV/AIDS vaccines in humansThe evolution of poxvirus vaccinesMucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in micePhase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individualsMagnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsTargeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens.Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory virusesMotivators to participation in medical trials: the application of social and personal categorization.Motivators to participation in actual HIV vaccine trials.Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.
P2860
Q21134955-8B7EDBA0-5DD4-42D2-B6F6-ED306039FACCQ24602593-04050536-04F6-46C8-8CE6-F2812FAD128DQ26995078-26255CBF-BCD4-406F-A6AA-8AA66BFD7277Q26995905-CCCCE939-8B78-4F2D-A470-6A6B3EB87FA5Q30375160-06176242-9F3E-4FB8-AA02-DB94C1CB2DC3Q30378897-754C6208-2C3C-4CC3-BD7E-86B71BFF1EADQ33737476-DFB1C9DE-1909-41A6-B7A2-A53CBFFE5D08Q33827771-04E08125-1CC2-45D6-88C2-2C782586B9ECQ34428899-A7988DF7-5092-4512-8D47-C2F63CA33535Q34592982-4A20A7E1-F5AF-411D-A5C1-0E777D4173DCQ34692141-C4ABFEB2-29B2-4C47-AB8B-51653DE8ACF7Q36083337-897EE67C-F1E1-4E85-AD92-715143B4C906Q36382421-4A62C6E1-4F75-43BE-9250-7A38702624A6Q36498186-25E975E1-C6C3-49F5-A96D-A6CB12BAC869Q37785949-D248F405-88B8-4993-A4DD-760D031CA2DFQ37948126-CF93872A-82BD-4EEB-B993-89F5FC960A67Q38077582-3F5B1BB3-A8CF-45FC-A08F-20970C2F7774Q38111996-ECEFF345-A538-4A57-82C0-B16952C62F69Q42166543-546D3F48-AF99-4848-A2D6-A32F3AA2A85B
P2860
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Lessons from a multisite inter ...... thout boosting with MN rgp120.
@en
type
label
Lessons from a multisite inter ...... thout boosting with MN rgp120.
@en
prefLabel
Lessons from a multisite inter ...... thout boosting with MN rgp120.
@en
P2093
P50
P1476
Lessons from a multisite inter ...... thout boosting with MN rgp120.
@en
P2093
026 Protocol Team and the NIAID HIV Vaccine Trials Network
Barbara J Metch
Dale N Lawrence
Donna J Eastman
Farley Cleghorn
Georgia D Tomaras
Javier R Lama
Jorge Sanchez
Marianne Hansen
P304
P356
10.1097/QAI.0B013E318149297D
P407
P577
2007-10-01T00:00:00Z